PDCD1 and non-small cell lung carcinoma: Actually, a meta-analysis has shown that anti-PD-1 achieves higher overall survival and response rate than anti-PD-L1 in NSCLC, which reveals anti-PD-1 as a better choice for patients with NSCLC (You et al., 2018).